메뉴 건너뛰기




Volumn 89, Issue 9, 2004, Pages 4729-4733

The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; GHRELIN; GLUCOSE; GROWTH HORMONE; INSULIN; PYRIDOSTIGMINE;

EID: 4544318339     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0656     Document Type: Article
Times cited : (49)

References (33)
  • 1
    • 0033540056 scopus 로고    scopus 로고
    • Ghrelin is a growth-hormone-releasing acylated peptide from stomach
    • Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
    • (1999) Nature , vol.402 , pp. 656-660
    • Kojima, M.1    Hosoda, H.2    Date, Y.3    Nakazato, M.4    Matsuo, H.5    Kangawa, K.6
  • 4
    • 0034687376 scopus 로고    scopus 로고
    • Ghrelin induces adiposity in rodents
    • Tschop M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908-913
    • (2000) Nature , vol.407 , pp. 908-913
    • Tschop, M.1    Smiley, D.L.2    Heiman, M.L.3
  • 10
    • 0344394289 scopus 로고    scopus 로고
    • Vagotomy dissociates short- and long-term controls of circulating ghrelin
    • Williams DL, Grill HJ, Cummings DE, Kaplan JM 2003 Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144:5184-5187
    • (2003) Endocrinology , vol.144 , pp. 5184-5187
    • Williams, D.L.1    Grill, H.J.2    Cummings, D.E.3    Kaplan, J.M.4
  • 11
    • 0035029806 scopus 로고    scopus 로고
    • The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia
    • Ahren B, Holst JJ 2001 The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 50:1030-1038
    • (2001) Diabetes , vol.50 , pp. 1030-1038
    • Ahren, B.1    Holst, J.J.2
  • 12
    • 0037220691 scopus 로고    scopus 로고
    • Plasma ghrelin concentrations are not regulated by glucose or insulin: A double-blind, placebo-controlled crossover clamp study
    • Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A 2003 Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 52:16-20
    • (2003) Diabetes , vol.52 , pp. 16-20
    • Schaller, G.1    Schmidt, A.2    Pleiner, J.3    Woloszczuk, W.4    Wolzt, M.5    Luger, A.6
  • 14
    • 0032952176 scopus 로고    scopus 로고
    • Neuroendocrine control of growth hormone secretion
    • Muller EE, Locatelli V, Cocchi D 1999 Neuroendocrine control of growth hormone secretion. Physiol Rev 79:511-607
    • (1999) Physiol Rev , vol.79 , pp. 511-607
    • Muller, E.E.1    Locatelli, V.2    Cocchi, D.3
  • 15
    • 0025159237 scopus 로고    scopus 로고
    • Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects
    • Penalva A, Muruais C, Casanueva FF, Dieguez C 1999 Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects. J Clin Endocrinol Metab 70:324-327
    • (1999) J Clin Endocrinol Metab , vol.70 , pp. 324-327
    • Penalva, A.1    Muruais, C.2    Casanueva, F.F.3    Dieguez, C.4
  • 16
    • 0022871815 scopus 로고
    • Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: Evidence for mediation by somatostatin
    • Locatelli V, Torsello A, Redaelli M, Ghigo E, Massare F, Muller EE 1986 Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin. J Endocrinol 111:271-278
    • (1986) J Endocrinol , vol.111 , pp. 271-278
    • Locatelli, V.1    Torsello, A.2    Redaelli, M.3    Ghigo, E.4    Massare, F.5    Muller, E.E.6
  • 17
    • 0036740389 scopus 로고    scopus 로고
    • Complete inhibition of hypothalamic somatostatin activity is only partially responsible for the growth hormone response to strenuous exercise
    • De Vries WR, Abdesselam SA, Sehers TJ, Maas HC, Osman-Dualeh M, Maitimu I, Koppeschaar HP 2002 Complete inhibition of hypothalamic somatostatin activity is only partially responsible for the growth hormone response to strenuous exercise. Metabolism 51:1093-1096
    • (2002) Metabolism , vol.51 , pp. 1093-1096
    • De Vries, W.R.1    Abdesselam, S.A.2    Sehers, T.J.3    Maas, H.C.4    Osman-Dualeh, M.5    Maitimu, I.6    Koppeschaar, H.P.7
  • 20
    • 0022456522 scopus 로고
    • Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in acromegaly and type I diabetes mellitus
    • Pietschmann P, Schernthaner G, Luger A 1986 Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in acromegaly and type I diabetes mellitus. J Clin Endocrinol Metab 63:389-393
    • (1986) J Clin Endocrinol Metab , vol.63 , pp. 389-393
    • Pietschmann, P.1    Schernthaner, G.2    Luger, A.3
  • 22
    • 0001118974 scopus 로고    scopus 로고
    • Muscarinic receptor agonists and antagonists
    • Hardman JG, Limbird LE, Gilman AG, eds. New York: McGraw-Hill Professional
    • Heller Brown J, Taylor P 2001 Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman, Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill Professional; 155-174
    • (2001) Goodman, Gilman's the Pharmacological Basis of Therapeutics , pp. 155-174
    • Heller Brown, J.1    Taylor, P.2
  • 28
    • 0030039638 scopus 로고    scopus 로고
    • Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli
    • Jaffe CA, DeMott-Friberg R, Barkan AL 1996 Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J Clin Invest 97:934-940
    • (1996) J Clin Invest , vol.97 , pp. 934-940
    • Jaffe, C.A.1    Demott-Friberg, R.2    Barkan, A.L.3
  • 29
    • 0141643291 scopus 로고    scopus 로고
    • Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes
    • Pöykkö SM, Kellokoski E, Hörkkö S, Kauma HY, Kesäniemi A, Ukkola O 2003 Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52:2546-2553
    • (2003) Diabetes , vol.52 , pp. 2546-2553
    • Pöykkö, S.M.1    Kellokoski, E.2    Hörkkö, S.3    Kauma, H.Y.4    Kesäniemi, A.5    Ukkola, O.6
  • 30
    • 0042626304 scopus 로고    scopus 로고
    • Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets
    • Colombo M, Gregersen S, Xiao J, Hermansen K 2003 Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets. Pancreas 27:161-166
    • (2003) Pancreas , vol.27 , pp. 161-166
    • Colombo, M.1    Gregersen, S.2    Xiao, J.3    Hermansen, K.4
  • 31
    • 0037372044 scopus 로고    scopus 로고
    • Dose-dependent inhibition by ghrelin of insulin secretion in the mouse
    • Reimer MK, Pacini G, Ahren B 2003 Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 144:916-922
    • (2003) Endocrinology , vol.144 , pp. 916-922
    • Reimer, M.K.1    Pacini, G.2    Ahren, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.